Home » Stocks » Novus Therapeutics

Novus Therapeutics, Inc. (NVUS)

Stock Price: $17.25 USD -0.02 (-0.12%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 18.58M
Revenue (ttm) n/a
Net Income (ttm) -17.80M
Shares Out 1.08M
EPS (ttm) -21.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $17.25
Previous Close $17.27
Change ($) -0.02
Change (%) -0.12%
Day's Open 17.39
Day's Range 17.12 - 17.66
Day's Volume 6,421
52-Week Range 4.50 - 26.10

More Stats

Market Cap 18.58M
Enterprise Value 10.05M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 1.08M
Float 1.03M
EPS (basic) -20.88
EPS (diluted) -21.27
FCF / Share -10.74
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 427,433
Short Ratio 0.04
Short % of Float 41.42%
Beta 2.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.22
Revenue n/a
Operating Income -13.06M
Net Income -17.80M
Free Cash Flow -10.13M
Net Cash 8.53M
Net Cash / Share 7.92
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -46.57%
ROE -140.22%
ROIC -1,977.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$23.70*
(37.39% upside)
Low
8.10
Current: $17.25
High
36.00
Target: 23.70
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-16.05-14.06-13.12-5.13-45.26-23.46-15.75-9.65
Net Income-16.01-14.07-13.12-5.66-45.09-23.30-15.73-9.65
Shares Outstanding11.809.014.680.382.500.720.050.03
Earnings Per Share-1.36-1.56-2.30-2.46-18.09-32.40-342.18-279.81
Operating Cash Flow-13.86-11.89-14.94-4.92-41.24-21.12-15.48-9.33
Capital Expenditures--0.01--0.57-0.03-0.02-0.01
Free Cash Flow-13.86-11.89-14.93-4.92-41.80-21.15-15.50-9.34
Cash & Equivalents8.7912.9717.301.1264.2310531.8011.71
Total Debt0.32--3.45----
Net Cash / Debt8.4712.9717.30-2.3364.2310531.8011.71
Assets10.9317.0320.891.2067.9710832.2911.96
Liabilities1.472.531.443.906.254.242.212.02
Book Value9.4714.4919.45-2.7061.72104-55.27-39.90
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Novus Therapeutics, Inc.
Country United States
Employees 7
CEO David-Alexandre C. Gros

Stock Information

Ticker Symbol NVUS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NVUS

Description

Novus Therapeutics, a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.